A number of new drugs are expected to be available in China; ESMO colon cancer guidelines are released; and new targeted drugs are released with new data. Tumor intelligence.

Every day 1 minute, give you the professional "talk material" in tumor circle! (if you need the original literature, you can get it through the wechat YXJ Oncology) Jie said that as a professional in the field of cancer, would you be used to brushing the tumor circle at night before going to bed? At the meeting, I met a big man in the academic circle, and I wanted to chat with him, but I didn't know where to start? The oncologists around are all talking about the magic medicine that will be on the market and the Shenwen that has just been issued, but you are so confused? It doesn't matter. "Cancer intelligence" is a news column tailored for you.from July 13, we will update every working day to push you the freshest, most professional and heaviest news of tumor circle! Friends who do not want to miss the daily column, please "Star" this official account! PS: this column has been recruiting part-time "intelligence officers" for a long time. If you are interested, please add the wechat YXJ oncology to chat in details; Oncology: global epidemiological data of tracheal, bronchial and lung cancer Discovery: amivanatamab shows initial effect on egfr20ins JCO: venetoclax combined with modified chemotherapy is effective and safe for elderly patients with acute myeloid leukemia New drugs: raptinib's marketing application has been accepted by nmpa for posterior line treatment of gastrointestinal stromal tumor; FDA has accepted the application for supplementary new drug from selinexor; it is used for the second line and above treatment of multiple myeloma; Oncology: global epidemiological data on tracheal, bronchial, and lung tumors are available. On July 20, the Journal of Hematology & amp; oncology published a study on the epidemiological trends of global, regional and national tracheal, bronchial, and lung (TBL) tumors.this study provides a comprehensive overview of the global burden of TBL.screenshot of the paper cover, this study assessed the cancer burden of TBL using data from the global burden of disease (GBD) database from 1990 to 2017.data on TBL cancer-related mortality and disability adjusted life years (DALYs) attributed to all known risk factors were also analyzed.the age standardized rate (ASR) and its estimated annual percentage change (EAPC) were calculated.study found that worldwide, TBL cancer incidence, death and DALYs increased (100.44%, 82.30% and 61.27% respectively); age standardized incidence rate (ASIR) was relatively stable, age standardized mortality rate (ASDR) and DALY rate were generally decreased., however, the trend of ASIR and ASDR between sexes is the opposite. China and the United States have been the highest incidence rate, mortality rate and DALY level of TBL cancer; tobacco is still the main cause of TBL cancer death and DALYs, followed by air pollution; the death rate and DALYs increase of TBL cancer and gender related to Xie Feng risk; the main age of TBL cancer incidence and death is more than 50 years old. DALYs were concentrated in 50-69 years old.in order to reduce the growing burden of TBL cancer, treatment resources need to be adjusted according to factors such as risk and geographical location, the researchers said.Asia has the largest burden of TBL cancer, followed by high-income North America.Tobacco and air pollution are the main causes of death and disability of TBL, and effective preventive measures against tobacco and air pollution should be strengthened.2Cancer discovery: amivantamab showed initial efficacy in the treatment of egfr20ins. On July 20, the Journal of cancer discovery reported that amivanatamab (a bispecific antibody targeting EGFR / CMET) showed good efficacy in the treatment of lung cancer with EGFR exon 20 insertional mutation (EGFR exon 20ins).amivanatamab is an egfr-met bispecific antibody with immunocyte targeting activity.in this study, it was confirmed that amivanatamab could inhibit proliferation by effectively downregulating EGFR / CMET levels and inducing the increase of IFN - γ secretion.studies have shown that amivanatamab produced a strong anti-tumor response in two patients with EGFR exon20ins: one 58 year old patient with EGFR h773delinsnpy mutation achieved partial remission, and the tumor shrank by 65%; the other patient with EGFR s768 had EGFR s768_ The 48 year old patients with d770dup mutation achieved partial remission, and the tumor size decreased by 38.9%.these patients did not progress in 92 weeks and 32 weeks after administration of amivanatamab.CT comparison of two cases before and after treatment 3jco: venetoclax combined with modified chemotherapy is effective and safe in the treatment of elderly acute myeloid leukemia (AML). On July 20, the Journal of clinical oncology published online a phase IB dose increase study of venetoclax combined with modified chemotherapy in the treatment of elderly acute myeloid leukemia (AML). venetola is a Bcl-2 inhibitor, and combination with modified chemotherapy is expected to alleviate AML in elderly patients. screenshot of the paper cover, 51 AML patients (≥ 65 years old or mononuclear karyotype ≥ 60 years old, both suitable for intensive chemotherapy), were assigned to the vinetura (50-600 mg) dose increasing cohort. the combination of 5 + 2 induction chemotherapy regimen: oral administration of venetula 14 days / cycle, the first 7 days (day-6 to 0) as the induction period, the dose of venetola gradually increased, the next 5 days (day1-5) combined with cytarabine (100 mg / m2), of which day2-3 were combined with idarubicin (12 mg / m2). to consolidate the four cycle administration regimen: oral administration of venetula (day-6-7) 14 days / cycle, day1-2 combined with cytarabine, Day1 combined with idarubicin. the oral administration of venetola was maintained for 7 cycles. the results of the study showed that the median age of 51 patients was 72 years old and did not reach the maximum tolerable dose of 600 mg / day. the main non hematological toxicity of venetula was febrile neutropenia (55%) and sepsis (35%). in contrast to the induction phase, platelet recovery was significantly delayed in the consolidation cycle. the overall response rate (ORR) was 72%, 97% in primary AML and 43% in secondary AML. in the early stage of venetula application, bone marrow progenitor cells in NPM1, idh2 and srsf2 mutant AML were reduced by more than 50%. b, C: comparison of recovery days of neutrophil and platelet count in different dose groups during induction period; D and E: comparison of recovery days of neutrophil and platelet count between induction period and each consolidation (CON) cycle. The researchers indicated that the combination of 5 + 2 induction chemotherapy regimen with venetola was safe and tolerable for elderly AML patients suitable for chemotherapy. 4The Lancet Oncology: preoperative chemoradiotherapy plus pazopanib can improve the pathological response rate of soft tissue sarcoma. On July 20, the Lancet Oncology published a multicenter, randomized, non blinded phase II clinical trial results of preoperative radiotherapy and chemotherapy for soft tissue sarcoma with or without pazopanib. This prospective trial found that preoperative neoadjuvant therapy with pazopanib was beneficial to disease control. a screenshot of the paper cover, the study included eligible adults (≥ 18 years old) and children (2 to & lt; 18 years old) from 57 hospitals in the United States and Canada. inclusion criteria: unresected, newly diagnosed chemotherapy sensitive soft tissue sarcoma of trunk or limbs (diameter greater than 5 cm, intermediate or advanced). between July 7, 2014 and October 1, 2018, a total of 81 eligible patients were enrolled and randomly divided into pazopanib group (n = 42) or control group (n = 39). all the patients received ifosfamide and doxorubicin, and received 45 Gy radiotherapy before surgery, and then underwent surgical resection at 13 weeks. the experimental group was given pazopanib orally, while the control group was not given pazopanib. the results showed that 14 patients (58%) in the pazopanib group (median follow-up of 0.8 years) achieved pathological remission of 90% or more; in the control group (median follow-up of 1 year), 4 patients (22%) achieved pathological remission of 90% or more, with a difference of 36.1% between the two groups. the pathological response rate of pazopanib combined treatment group exceeded the preset boundary, and the adverse reactions were relatively low. in this first prospective trial of soft tissue sarcomas covering almost the entire age spectrum, the addition of pazopanib to neoadjuvant chemoradiotherapy improved the incidence of pathological near complete remission, suggesting that patients with advanced soft tissue sarcomas may benefit from preoperative treatment with pazopanib. 5 guidelines: ESMO clinical practice guidelines for localized colon cancer were released July 20, annals of Oncology has released the latest clinical practice guidelines of the European Society of Oncology (ESMO) on localized colon cancer, which was written by a multidisciplinary expert group composed of European institutions and countries. It provides important suggestions for the treatment of localized colon cancer, and updates the treatment recommendations based on new evidence. for the adjuvant treatment of stage III colon cancer, the guideline suggests that the combination of fluorouracil, 5-FU or capecitabine and oxaliplatin constitutes the basis of adjuvant therapy for stage III colon cancer [I, a]. the duration of adjuvant therapy for oxaliplatin based stage III colon cancer can be adjusted as: capox is 3 or 6 months, FOLFOX is 6 months. Pathological risk characteristics, patient complications and risk assessment should also be considered [I, a]. treatment was further adjusted according to the risk group: capox (t1-3 N1 disease) 3 months, capox (T4 or N2 disease) 6 months, FOLFOX (t1-3 N1 or T4 or N2 disease) 6 months [v]. capecitabine or lv5fu2 (de Gramont) infusion can be used as adjuvant therapy for 6 months in patients who are not suitable or intolerant of oxaliplatin [I, a]. adjuvant therapy for stage III colon cancer: for adjuvant treatment of stage II colon cancer, it is recommended that patients with low-risk stage II colon cancer should be followed up [I, a]. 6-month fluorouracil should be recommended for moderate risk patients [non mismatch repair / microsatellite instability (MMR / MSI) + any risk factors other than pT4 or & lt; 12 lymph nodes]. Patients with stage II high-risk (pT4 or & lt; 12 lymph node metastasis or multiple intermediate risk factors, regardless of MSI) can be considered for the addition of oxaliplatin [I, C]. patients with stage II high-risk colon cancer can be treated with capox for 3 months. Br / > it is recommended that adjuvant chemotherapy should be started as early as possible after surgery for colon cancer. 6 new drugs: four new anti-cancer drugs are planned to be included in the national priority review, and are expected to be approved for listing. According to the latest information published on the website of the drug evaluation center (CDE) of the State Drug Administration (nmpa), five innovative drugs have been listed in the list of priority review varieties, including four anti-tumor drugs: voritinib and avapritinib ）And triprilimab as well as pamimipari capsules. ① voritinib is a potent and highly selective oral small molecule met inhibitor. Met is a receptor tyrosine kinase with abnormal function in many types of solid tumors. in May this year, the new drug marketing application of voritinib was submitted to nmpa and accepted for the treatment of non-small cell lung cancer (NSCLC) with met exon 14 mutation, which is also the first new drug marketing application submitted by voritinib in the world. ② APOOn July 20, zaiding pharmaceutical and deciphera pharmaceuticals jointly announced that nmpa had accepted a new drug application for ripretinib for the treatment of adult patients with advanced GIST who had received three or more kinase inhibitors including imatinib. the application for the market of reptinib is based on a phase III randomized, double-blind, placebo-controlled international multicenter clinical trial Invictus. The purpose of this study is to evaluate the safety, tolerability and efficacy of raptinib compared with placebo in 129 patients with advanced GIST. The patients have previously received imatinib, sunitinib and regofinib treatment. according to previous reports, the median progression free survival (PFS) of the study was 6.3 months, compared with 1.0 months in the placebo group, and the risk of disease progression or death was significantly reduced by 85% (hazard ratio 0.15, P & lt; 0.0001). the orr of reptinib was 9.4%, compared with 0% in placebo group (P = 0.0504). the median OS of reptinib was 15.1 months, compared with 6.6 months in the placebo group, and the risk of death was reduced by 64% (hazard ratio was 0.36). 8 new drugs: FDA has accepted the application of selinexor for second-line and above-line treatment of multiple myeloma. On July 20, NASDAQ listed company karyopharm therapeutics announced that FDA had accepted its selinexor supplementary drug application (SNDA) for line 2 and above treatment of multiple myeloma. selinexor is a novel oral selective nuclear output inhibitor (sine), which can reversibly inhibit the nuclear output of tumor suppressor protein (TSP), growth regulator and carcinogenic protein mRNA by blocking export protein 1 (xpo1). by inhibiting xpo1, selinexor can lead to TSP accumulation in nucleus, decrease of protease, cell cycle arrest and apoptosis of cancer cells, but it has no significant effect on normal cells. it is reported that the approval of the drug depends on the results of its phase III clinical trials. Compared with patients treated with bortezomib and low-dose dexamethasone alone, the addition of xpo1 mediated nuclear output inhibitor to bortezomib and low-dose dexamethasone showed that the triple therapy not only improved PFS and objective response rate (ORR), but also reduced peripheral neuropathy in these patients The incidence of change. reference information: [1] Deng, Y., Zhao, P., Zhou, L. et al. Empirical trends of traceal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study. J Hematol Oncol 13, 98 (2020). Yun, soo Hwan Lee, Seok young Kim, et al. Antitumor activity of amivanatamab (jnj-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. Cancer Discovery. 2020. DOI: 10.1158/2159-8290.CD-20-0116[3]Chong Chyn Chua , Andrew W. Roberts , John Reynolds , et al. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. Journal of Clinical Oncology. 2020[4]Aaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. The Lancet Oncology. 2020.DOI: Argiles , J. Tabernero , R. Labianca , et al. Localised Colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2020 [6] ▍